NASDAQ: EXEL
Exelixis Inc Stock

$35.82-0.22 (-0.61%)
Updated Dec 6, 2024
EXEL Price
$35.82
Fair Value Price
$72.05
Market Cap
$10.23B
52 Week Low
$19.20
52 Week High
$36.97
P/E
22.67x
P/B
4.5x
P/S
3.56x
PEG
2x
Dividend Yield
N/A
Revenue
$2.08B
Earnings
$466.92M
Gross Margin
96.3%
Operating Margin
28.82%
Profit Margin
22.4%
Debt to Equity
0.3
Operating Cash Flow
$470M
Beta
0.73
Next Earnings
Feb 4, 2025
Ex-Dividend
N/A
Next Dividend
N/A

EXEL Overview

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine EXEL's potential to beat the market

AStrong Buy
  • Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More

Zen Rating Component Grades

A
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
B
Financials
B
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
EXEL
Ranked
#11 of 554

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$25.45A
$6.72A
$19.82A
View Top Biotech Stocks

Be the first to know about important EXEL news, forecast changes, insider trades & much more!

EXEL News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EXEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

EXEL ($35.82) is undervalued by 50.29% relative to our estimate of its Fair Value price of $72.05 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
EXEL ($35.82) is significantly undervalued by 50.29% relative to our estimate of its Fair Value price of $72.05 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
EXEL ($35.82) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EXEL due diligence checks available for Premium users.

Valuation

EXEL fair value

Fair Value of EXEL stock based on Discounted Cash Flow (DCF)

Price
$35.82
Fair Value
$72.05
Undervalued by
50.29%
EXEL ($35.82) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EXEL ($35.82) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EXEL ($35.82) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

EXEL price to earnings (PE)

For valuing profitable companies with steady earnings

Company
22.67x
Industry
-105.55x
Market
29.86x
EXEL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
EXEL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

EXEL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
4.5x
Industry
5.68x
EXEL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

EXEL price to earnings growth (PEG)

For valuing profitable companies with growth potential

EXEL is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

EXEL's financial health

Profit margin

Revenue
$539.5M
Net Income
$118.0M
Profit Margin
21.9%
EXEL's Earnings (EBIT) of $599.91M... subscribe to Premium to read more.
Interest Coverage Financials
EXEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.0B
Liabilities
$684.9M
Debt to equity
0.3
EXEL's short-term assets ($1.55B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EXEL's short-term assets ($1.55B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EXEL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
EXEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$271.3M
Investing
-$217.1M
Financing
$5.7M
EXEL's operating cash flow ($470.28M)... subscribe to Premium to read more.
Debt Coverage Financials

EXEL vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
EXELA$10.23B-0.61%22.67x4.50x
ROIVF$9.00B+2.32%2.08x1.75x
PCVXD$11.63B+3.63%-20.28x3.40x
TECHB$11.84B+0.84%78.43x5.54x
SRPTB$12.24B+1.50%82.16x10.03x

Exelixis Stock FAQ

What is Exelixis's quote symbol?

(NASDAQ: EXEL) Exelixis trades on the NASDAQ under the ticker symbol EXEL. Exelixis stock quotes can also be displayed as NASDAQ: EXEL.

If you're new to stock investing, here's how to buy Exelixis stock.

What is the 52 week high and low for Exelixis (NASDAQ: EXEL)?

(NASDAQ: EXEL) Exelixis's 52-week high was $36.97, and its 52-week low was $19.20. It is currently -3.11% from its 52-week high and 86.56% from its 52-week low.

How much is Exelixis stock worth today?

(NASDAQ: EXEL) Exelixis currently has 285,579,020 outstanding shares. With Exelixis stock trading at $35.82 per share, the total value of Exelixis stock (market capitalization) is $10.23B.

Exelixis stock was originally listed at a price of $14.75 in Apr 17, 2000. If you had invested in Exelixis stock at $14.75, your return over the last 24 years would have been 142.85%, for an annualized return of 3.77% (not including any dividends or dividend reinvestments).

How much is Exelixis's stock price per share?

(NASDAQ: EXEL) Exelixis stock price per share is $35.82 today (as of Dec 6, 2024).

What is Exelixis's Market Cap?

(NASDAQ: EXEL) Exelixis's market cap is $10.23B, as of Dec 8, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Exelixis's market cap is calculated by multiplying EXEL's current stock price of $35.82 by EXEL's total outstanding shares of 285,579,020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.